IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i19p12366-d928216.html
   My bibliography  Save this article

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Author

Listed:
  • Gyeyoung Choi

    (College of Pharmacy, Ewha Womans University, Seoul 03760, Korea)

  • Gyeongseon Shin

    (College of Pharmacy, Ewha Womans University, Seoul 03760, Korea)

  • SeungJin Bae

    (College of Pharmacy, Ewha Womans University, Seoul 03760, Korea)

Abstract

Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence. In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility cost increase the financial burden considering the frequency of adverse events such as cytokine release syndrome. In clinical research, relatively short follow-up periods were used compared to traditional cancer agents. In addition, head-to-head comparative effectiveness data are unavailable, which is an important factor when evaluating the cost-effectiveness of a new treatment. Additional evidence that will compensate for the uncertainty of existing clinical data is needed for full evaluation of long-term efficacy, safety, and comparative effectiveness.

Suggested Citation

  • Gyeyoung Choi & Gyeongseon Shin & SeungJin Bae, 2022. "Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy," IJERPH, MDPI, vol. 19(19), pages 1-6, September.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12366-:d:928216
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/19/12366/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/19/12366/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12366-:d:928216. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.